Soleno Therapeutics Inc Aktie News

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ:SLNO) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.

REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced a publication in the peer-reviewed Journal of Clinical Endocrinology and Metabolism (JCEM). The paper, titled, “Diazoxide Choline Extended-Release Tablets in Prader-Willi Syndrome:...

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ:SLNO). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Hap...

SAN DIEGO , Dec. 15, 2025 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether Soleno Therapeutics, Inc. (NASDAQ: SLNO) or certain of its officers and directors violated federal securities laws by making false or misleading statements and/or failing to disclose material information to investors. The investigation also examines whether Soleno's public communi...

SAN DIEGO , Dec. 4, 2025 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether Soleno Therapeutics, Inc. (NASDAQ: SLNO) or certain of its officers and directors violated federal securities laws by making false or misleading statements and/or failing to disclose material information to investors. The investigation also examines whether Soleno's public communic...

Connecticut-based fund Braidwell bought nearly 1.3 million shares in Soleno Therapeutics during the third quarter. As a result, the net position change from quarter to quarter was about $86.7 million.

REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today regrets to announce the passing of William G. “Bill” Harris, who served as a valued member of Soleno's Board of Directors since June 2014. Mr. Harris also served as Chairman of the Audit Com...

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether Soleno Therapeutics, Inc. (NASDAQ: SLNO) or certain of its officers and directors violated federal securities laws by making false or misleading statements and/or failing to disclose material information to investors.